Incidence of Primary Soft Tissue Sarcoma Diagnosed on Extremities and Trunk Wall

A Population-Based Study in Taiwan

Giu-Yi Hung, MD, Chueh-Chuan Yen, MD, PhD, Jin-Lin Horng, PhD, Chun-Yu Liu, MD, PhD, Wei-Ming Chen, MD, Tain-Hsiung Chen, MD, and Chien-Lin Liu, MD

Abstract: Most epidemiological studies of soft tissue sarcoma (STS) were performed in the Western countries, and only limited data highlighting that in the Asian population. The aim of this study is to conduct a comprehensive analysis for the incidence rates of STS in Taiwan.

This was a population-based study analyzing the incidence rates and trends of the primary STS over extremities and trunk wall during 2003 to 2011 by using the nationwide Taiwan Cancer Registry. More specific analyses were conducted for subtypes. Incidence rates of overall STS by cities and counties were also investigated.

A total of 3843 cases were diagnosed with STS during the study period, giving an age-standardized rate (ASR) of 1.63 per 100,000 person-years. Liposarcoma was the most frequent subtype, followed by undifferentiated pleomorphic sarcoma and leiomyosarcoma. STS was more frequently diagnosed in males and angiosarcoma was the most prominent sex-specific type. ASR increased with age in most of the STS subtypes and varied by histologic subtype. The incidence of peripheral primitive neuroectodermal tumor was highest in children, whereas rhabdomyosarcoma revealed a bimodal age distribution. Annual percent change (APC) of STS was 2.2%, and significant change in trend was only in males (APC, 3.5%, P < 0.05). Geographical variations indicated that New Taipei City had a significantly higher rate compared with the rest areas. Significantly lower rates were observed in 1 major offshore island.

Incidence variations of STS by sexes, ages, histologic subtypes, and geographic regions were observed in Taiwanese population. The emerging factors associated STS incidence rates deserve further studies to verify.

(int) Medicine 94(41):e1696

Abbreviations: APC = annual percent change, ASR = age-standardized incidence rate, CI = confidence intervals, DCO = death certificate only, IARC = International Agency for Research on Cancer, M/F = male-to-female, MV = microscopy-verified, NF1 = neurofibromatosis type 1, NOS = not otherwise specified, pPNET = peripheral primitive neuroectodermal tumor, SEER = Surveillance, Epidemiology, and End Results Program, SRR = standardized incidence rate ratio, STS = soft tissue sarcomas, TCR = Taiwan Cancer Registry, UPS = undifferentiated pleomorphic sarcoma.

INTRODUCTION

Soft tissue sarcomas (STS) are rare and heterogeneous diseases accounting for less than 1% of the diagnosed malignancy and are widely found in the connective tissues throughout the human body. STS spans a broad range of differentiation including adipocytes (liposarcoma), peripheral nerve tissues (malignant peripheral nerve sheath tumor), smooth (leiomyosarcoma) or striated muscle (rhabdomyosarcoma), vascular tissues (angiosarcoma), and the other unknown origins (such as undifferentiated pleomorphic sarcoma).2 Due to the rarity and complexity of STS, large population-based studies are required to elucidate the incidences and the potential contributing factors.

Most of the previous population-based studies on the STS were conducted in the Western countries and the reported incidences ranged from 1.8 to 5.0 per 100,000 annually.3-9 In recent years, an increasing incidence of STS has also been revealed in several studies.3-6 However, specific data on STS in the Asia-Pacific region are rare,10 and only 2 studies reporting the incidence patterns of sarcomas in Asia are available.11,12 By using the nationwide Taiwan Cancer Registry (TCR) database, the incidences related to bone cancer in the Taiwanese population have been reported in our previously published results.1,2 In this study, the TCR database was used for a comprehensive analysis of incidences and trends of STS over the extremities and trunk wall. Furthermore, geographic variations in the incidence of STS were also analyzed.
MATERIAL AND METHODS
Data Qualification and Acquirement
The data of primary soft tissue cancers diagnosed and
registered in the TCR database during 2003 and 2011 were
acquired.14 Soft tissue cancers were classified according to the
International Classification of Diseases for Oncology, version 3
(ICD-O-3: C47, C49 cancer of connective, subcutaneous, and
other soft tissues).15 The data included the soft tissue cancers
over extremities and trunk wall, but those from central nervous
system, head and neck regions, breast, intrathoracic and intraab-
donimal cavities, endocrine system, and skin were excluded. In
TCR, the primary soft tissue cancers were further stratified into
the subgroups including undifferentiated pleomorphic sarcoma
(UPS, including malignant fibrohistiocytoma and fibrosar-
coma), liposarcoma, leiomyosarcoma, rhabdomyosarcoma,

### TABLE 1. Incidence (Per 100,000 Person-Yr) of Primary Soft Tissue Cancers by Sex and Histologic Subtype, Taiwan (2003–2011)

| Histologic Subtype                                      | Sex   | n     | Crude Rate | ASR<sup>a</sup> | 95% CI     | SRR  | 95% CI   | MV% |
|--------------------------------------------------------|-------|-------|------------|-----------------|------------|------|----------|-----|
| All types                                              | Both sexes | 3843  | 1.86       | 1.63            | 1.58–1.68  |      |          | 97.6|
|                                                        | Male   | 2211  | 2.12       | 1.87            | 1.79–1.95  | 1.34† | 1.26–1.43|     |
|                                                        | Female | 1632  | 1.60       | 1.39            | 1.32–1.46  |      |          |     |
| Undifferentiated pleomorphic sarcoma                   | Both sexes | 728   | 0.35       | 0.29            | 0.27–0.32  |      |          | 99.5|
| Liposarcoma                                            | Male   | 432   | 0.41       | 0.35            | 0.32–0.38  | 1.48† | 1.28–1.71|     |
|                                                        | Female | 296   | 0.29       | 0.24            | 0.21–0.26  |      |          |     |
| Leiomyosarcoma                                         | Male   | 537   | 0.51       | 0.44            | 0.40–0.48  | 1.58† | 1.39–1.80|     |
|                                                        | Female | 348   | 0.34       | 0.28            | 0.25–0.31  |      |          |     |
| Rhabdomyosarcoma                                       | Male   | 292   | 0.14       | 0.12            | 0.10–0.13  | 1.09  | 0.87–1.37|     |
|                                                        | Female | 150   | 0.14       | 0.12            | 0.10–0.14  |      |          |     |
| Angiosarcoma                                           | Male   | 115   | 0.11       | 0.12            | 0.10–0.14  | 1.18  | 0.88–1.58|     |
|                                                        | Female | 86    | 0.08       | 0.10            | 0.08–0.13  |      |          |     |
| Synovial sarcoma                                       | Male   | 282   | 0.14       | 0.11            | 0.10–0.13  | 1.79† | 1.42–2.26|     |
|                                                        | Female | 182   | 0.17       | 0.15            | 0.12–0.17  |      |          |     |
| Malignant nerve sheath tumor (including malignant schwannoma) | Male   | 117   | 0.11       | 0.10            | 0.08–0.12  | 1.05  | 0.80–1.36|     |
|                                                        | Female | 105   | 0.10       | 0.10            | 0.08–0.11  |      |          |     |
| Peripheral primitive neuroectodermal tumor             | Both sexes | 112   | 0.05       | 0.07            | 0.05–0.08  |      |          | 97.6|
| Other specified sarcoma                                | Male   | 66    | 0.06       | 0.08            | 0.06–0.10  | 1.31  | 0.89–1.93|     |
|                                                        | Female | 46    | 0.05       | 0.06            | 0.04–0.08  |      |          |     |
| Sarcoma NOS                                            | Male   | 289   | 0.28       | 0.24            | 0.21–0.27  | 1.29† | 1.08–1.53|     |
|                                                        | Female | 230   | 0.23       | 0.19            | 0.16–0.21  |      |          |     |
| Other malignancy†                                      | Male   | 200   | 0.19       | 0.16            | 0.14–0.19  | 1.47† | 1.19–1.83|     |
|                                                        | Female | 137   | 0.13       | 0.11            | 0.09–0.13  |      |          |     |
| Other malignancy†                                      | Male   | 93    | 0.05       | 0.04            | 0.03–0.05  | 1.12  | 0.74–1.67|     |
|                                                        | Female | 45    | 0.04       | 0.04            | 0.03–0.05  |      |          |     |

ASR = age-standardized incidence rate; CI = confidence interval; MV% = percentage of microscopically verified cases; NOS = not otherwise specified; SRR = male-to-female standardized incidence rate (ASR) ratio.

<sup>a</sup>ASRs were age-standardized to the 2000 world standard population.

† Indicates statistical significance at the 0.01 level.
angiosarcoma, synovial sarcoma, malignant nerve sheath tumor (including malignant schwannoma), peripheral primitive neuroectodermal tumor (pPNET), other specified sarcoma (including spindle cell sarcoma, giant cell sarcoma, small cell sarcoma, epithelioid sarcoma, and so on), sarcoma not otherwise specified (NOS), and other malignancy (including carcinomas, malignant mesenchymoma, and other nonsarcoma neoplasms). Lymphoma and multiple myeloma were excluded in the current study, except for analyzing the geographical variations. Census and land data were obtained from the Department of Statistics, Ministry of the Interior, Taiwan.16

The TCR have collected cancer data since 1979. Regarding the data quality defined by the International Agency for Research on Cancer (IARC), improvements in the percentage of microscopy-verified registration (MV, %) and decreased percentage of death certificate only (DCO, %) were demonstrated in previous reports.17,18 In Taiwan, the Cancer Control Act effective in 2003 began mandating that all the hospitals implemented with >50 beds need to submit cancers data to the central registry. For all cancers registration, the ratio of MV was raised from 85.6% in 2003 to 91.6% in 2011, and the percentage of DCO was lowered from 2.7% to 0.82% during the same period. In fact, the variations in these indicators were markedly reduced than the years before 2003. These indicators demonstrated that the completeness and validity of TCR have been enhanced by mandated registration since 2003. Therefore, the present study was designed to acquire the data registered in the period between 2003 and 2011.

The dataset used in this study was obtained from TCR, Health Promotion Administration, Ministry of Health and Welfare, Taiwan (http://tcr.cph.ntu.edu.tw/main.php?page=A1, http://tcr.cph.ntu.edu.tw/main.php?page=SA3&KeyID=1903882774544356b5ece3, and http://www.hpa.gov.tw/BHPNet/Web/Stat/Statistics.aspx). These data are publicly available and do not contain any identifiable personal information. Based on Taiwan regulations, ethical approval was waived for studies using these data (such as ours).

Data Analysis

This study employed IARC’s published methods to calculate the incidence, standard errors, 95% confidence intervals (CI), and standardized incidence rate ratio (SRR).19,20 Age-specific incidences were stratified into 18 subgroups by 5-year age interval (0–4 to 85+ years). An age-standardized incidence rate (ASR) is a weighted average of the age-specific (crude) rate, where the weight is the proportion of individuals in the corresponding age group of a standard population. Calculating the ASRs of subgroups using the same standard population can correct the potential confounding effect derived from the differences in ages. In this study, the world standard population in 2000 was used to calculate the ASRs and to examine geographic variations. The trends were analyzed by using the joinpoint regression model and permutation tests (Joinpoint Regression Program, version 4.0.4; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute, Bethesda, MD) to identify significant changes,21,22 in which up to 2 joinpoints were produced to express the annual percent change (APC). The APC was considered significant if the 95% CI did not include 0. The relative risks of cancer, ratio of ASRs (SRRs), and 95% CI were calculated to compare the cancer incidences by cities/counties. The SRRs were considered significantly different if the estimated 95% CI did not contain 1. To avoid the effect of comparing heavily populated cities/counties (eg, New Taipei City, with 16.3% of the total population), which is itself affected by their contribution, the rate for each city/county was compared with the rest area of Taiwan (eg, New Taipei City vs. Taiwan-minus-New Taipei City).

RESULTS

A total of 3843 subjects were diagnosed as primary soft tissue cancer during the 9-year study period with a crude rate of 1.86 and an ASR of 1.63 in 100,000 (Table 1). The cumulative risk developing soft tissue cancer from birth to age 74 years (or age 84 yr) was 0.15% (0.22%). Soft tissue cancer comprised 0.6% of the diagnosed cancers in 2003, and 0.51% in 2011. The median age of the registered soft tissue cancers was 51 years in 2003, and 56 years in 2011. This result implied the growing trend of aging population in Taiwan. Liposarcoma was the most common subtype, accounting for 23% of soft tissue cancers, followed by UPS (18.9%) and leiomyosarcoma (7.6%). The 3 subtypes comprised approximately half of all primary soft tissue cancers diagnosed in Taiwanese population. Soft tissue cancers were more frequently diagnosed in males than females. The male-to-female (M/F) SRR was 1.34 (P < 0.01). In addition, males were significantly more susceptible to the cancer subtypes including UPS, liposarcoma, angiosarcoma, other specified sarcoma, and sarcoma NOS, with the SRRs ranging between 1.29 and 1.79. The most prominent sex difference was found in angiosarcoma (M/F SRR = 1.79, 95% CI, 1.42–2.26, P < 0.01). By contrast, the lowest M/F SRR was found for synovial sarcoma (M/F SRR = 0.74), although not statistically
significant. The percentage of MV was variable between 94.8% and 100% for all acquired subtypes of soft tissue cancers data but that of the subtype “other malignancy” showed a lower MV rate, 63.9% (Table 1).

**Age-Specific Incidences**

The age-specific incidences of soft tissue cancer increased with age and peaked for the elderly population (Figure 1A). The incidences of UPS (Figure 1B), liposarcoma (Figure 1C), leiomyosarcoma (Figure 1D), and angiosarcoma (Figure 1E) showed a similar trend among the different age groups. It was slowly increased for the population aged 30 to 50 years, a rapid increase was found in the age group of 60 to 70 years, and the highest incidence was shown in the population aged 85 and over. It is noteworthy that an exceptionally decreased incidence of liposarcoma in the population older than those

## Table 2. Annual Percent Changes in Incidence Rates of Primary Soft Tissue Cancers by Sex and Histologic Subtype, Taiwan (2003–2011)

| Histologic Subtype                               | Sex          | Year     | APC* | 95% CI       |
|-------------------------------------------------|--------------|----------|------|--------------|
| All types                                       | Both sexes   | 2003–2011| 2.2  | 0.3–4.1      |
|                                                | Male         | 2003–2011| 3.5  | 1.1–6.0      |
|                                                | Female       | 2003–2011| 0.5  | –2.5–3.6     |
| Undifferentiated pleomorphic sarcoma            | Both sexes   | 2003–2011| –0.7 | –4.0–2.8     |
|                                                | Male         | 2003–2011| 2.0  | –2.9–7.1     |
|                                                | Female       | 2003–2011| –4.2 | –8.1 to –0.2 |
| Liposarcoma                                     | Both sexes   | 2003–2011| 4.2  | 0.5–8.1      |
|                                                | Male         | 2003–2011| 5.3  | 2.4–8.2      |
|                                                | Female       | 2003–2011| 2.8  | –3.2–9.0     |
| Leiomyosarcoma                                  | Both sexes   | 2003–2011| 0.7  | –3.5–5.1     |
|                                                | Male         | 2003–2011| –1.4 | –4.4–1.7     |
|                                                | Female       | 2003–2011| 2.5  | –4.5–10.0    |
| Rhabdomyosarcoma                                | Both sexes   | 2003–2011| 4.4  | –8.6–0.1     |
|                                                | Male         | 2003–2011| –5.0 | –12.9–3.6    |
|                                                | Female       | 2003–2011| –3.2 | –12.5–7.0    |
| Angiosarcoma                                    | Both sexes   | 2003–2011| 6.4  | –1.3–14.7    |
|                                                | Male         | 2003–2011| 6.8  | –5.4–20.5    |
|                                                | Female       | 2003–2011| 6.2  | –2.0–15.2    |
| Synovial sarcoma                                | Both sexes   | 2003–2011| 3.2  | –1.8–8.4     |
|                                                | Male         | 2003–2011| 6.5  | –0.6–14.0    |
|                                                | Female       | 2003–2011| 0.8  | –6.8–9.1     |
| Malignant nerve sheath tumor                    | Both sexes   | 2003–2011| 2.0  | –8.0–13.1    |
| (including malignant schwannoma)               | Male         | 2003–2011| 8.7  | –3.3–22.2    |
|                                                | Female       | 2003–2011| –4.4 | –13.9–6.1    |
| Peripheral primitive neuroectodermal tumor     | Both sexes   | 2003–2011| 4.3  | –4.4–13.8    |
|                                                | Male         | 2003–2011| 8.4  | –2.6–20.6    |
|                                                | Female       | 2003–2011| –2.3 | –13.1–10.0   |
| Other specified sarcoma                         | Both sexes   | 2003–2011| 4.4  | –0.7–9.7     |
|                                                | Male         | 2003–2011| 3.7  | 1.3–6.1      |
|                                                | Female       | 2003–2011| 5.6  | –4.4–16.5    |
| Sarcoma NOS                                     | Both sexes   | 2003–2011| 2.0  | –8.0–13.2    |
|                                                | Male         | 2003–2011| 4.0  | –5.8–14.8    |
|                                                | Female       | 2003–2011| –0.4 | –11.7–12.3   |
| Other malignancy                                | Both sexes   | 2003–2011| 0.4  | –10.3–12.4   |
|                                                | Male         | 2003–2011| –3.2 | –12.4–7.1    |
|                                                | Female       | 2003–2011| 4.2  | –8.9–19.0    |

APC = annual percent change; CI = confidence interval; NOS = not otherwise specified.

* The APC was calculated via weighted least-squares regression.

† Indicates statistical significance at the 0.05 level.
aged 75 to 79. The age-specific incidence of rhabdomyosarcoma (Figure 1F) revealed a bimodal distribution, showing a peak incidence in children and young adults and another peak amongst the elderly. The age-specific incidence of synovial sarcoma (Figure 1G) was increased in the adolescent population and remained stable throughout the ages from 15 to 79. The incidence of malignant nerve sheath tumor (Figure 1H) steadily increased since early childhood, and peaked in the elderly. In contrast to most subtypes of soft tissue cancers with incidences peaking in the elderly, pPNET (Figure 1I) was the most frequently diagnosed cancer in early childhood aged 0 to 4 years. The incidence was lowered thereafter and remained stable up to age 10 to 20 years. It became rarely found in those aged over 20 years but a slight increase in incidence was found in the elderly.

### Temporal Trends

The annual changes in incidence of soft tissue cancers by histologic subtypes between 2003 and 2011 are demonstrated in Table 2 and Figure 2. There was a statistically significant change in the trend for all soft tissue cancers, with an average APC of 2.2% (95% CI, 0.3–4.1%, P < 0.05, Table 2). Specifically, the significant increasing trend was only found in males (APC, 3.5%; 95% CI, 1.1–6.0%, P < 0.05, Table 2 and Figure 2A). In terms of histologic subtypes, significant decreasing trend in incidence rates was only found in females diagnosed with UPS (APC, −4.2%, Figure 2B), whereas annual changes in incidences of liposarcoma (APC = 5.3%, Figure 2C) and other specified sarcoma (APC = 3.7%, Figure 2D) revealed significantly upward trends in males.

### Geographical Variations

The incidences of primary soft tissue cancers calculated by 22 cities/counties during the 9-year study period are shown in Table 3. The dataset used for analyzing geographical variations in overall soft tissue cancers did not contain information for specific subtypes. Therefore, lymphoma and multiple myeloma were both included, giving a total case numbers of 4002 instead of 3843. The SRRs calculated for each city/county were also demonstrated in Table 3. Significance difference in the incidence was only found in 2 cities/counties. New Taipei City had a significantly higher rate (SRR = 1.11, 95% CI, 1.02–1.21, P < 0.05). By contrast, Penghu county (an offshore island) showed significantly lower rate (SRR, 0.60).

### DISCUSSION

In this study, a total of 3843 subjects were diagnosed with soft tissue cancer during the study period in the TCR database, giving an ASR of 1.63 per 100,000 person-years. ASR of our patient population was lower than those reported by previous studies from Western countries (including all sites), and slightly higher than that reported in Korea (extremity only). The differences could be attributed to different tumor sites included and analyzed. Liposarcoma was the subtype with the highest incidence of STS in this study, but ranked third in most reports of Western countries. Males had a significantly higher risk of angiosarcoma than females in Taiwanese population (M/F SRR, 1.79, P < 0.01). Similar results with a sex-specific difference in risk of angiosarcoma (ASR = 2.0) were shown in The Surveillance, Epidemiology, and End Results Program (SEER) of the National Cancer Institute of USA that investigated cutaneous STS. Recently, several hot spots of genomic aberrations were found in angiosarcoma cells. The association between the genetic changes and the susceptibility to angiosarcoma found in males deserves further investigation to elucidate.

For most of STS, the age-specific incidence increased with age, except a higher frequency of pPNET in children. The
incidence patterns of rhabdomyosarcoma revealed a bimodal age distribution. Increased rates comprised 2 clusters, 1 for embryonal and alveolar rhabdomyosarcoma in childhood and adolescence, and 1 for pleomorphic rhabdomyosarcoma in elderly population. These findings were comparable with the previous study from SEER. In addition, the incidence of liposarcoma showed a downward trend for the population older than 75 to 79 years. Similar observations from the SEER report have indicated a decreased incidence in dedifferentiated liposarcoma may contribute to a lower frequency of liposarcoma in the population aged older than 75 to 80 years. Only few studies have been conducted to investigate the incidence patterns for synovial sarcoma and malignant nerve sheath tumor. Earlier studies have shown that synovial sarcoma was rarely seen in children. Patient age at initial diagnosis distributed over a wide range (6–82 yr), with the majority of patients presented between 15 and 40 years of age. In this study, the incidence of synovial sarcoma increased in adolescents and remained stable throughout the ages of 15 to 79 years. This is consistent with previous single institution reports such as those from Memorial Sloan Kettering Cancer Center at USA (cases age ranged from 16 to 80) or Rizzoli Orthopedic Institute at Bologna, Italy (more than 80% of cases diagnosed within 18–65 age range). On the other hand, the published studies have shown that the peak incidence of malignant nerve sheath tumor was found in those aged 30 to 50 years. However, patients suffering from malignant nerve sheath tumor with neurofibromatosis type 1 (NF1) were younger than those without NF1, and about one third of those non-NF1 patients aged older than 60 years at diagnosis. The present study demonstrated the evidences that an increased incidence of malignant nerve sheath tumor was found during the years of childhood and it was raised dramatically in the elderly. The results of our study were in line with previous observations, suggesting the high incidence in the elderly was most likely contributed by those patients without NF1. In combination, the multiple perspectives in the incidences of STS subtypes were associated with the complex nature of these diseases.

Nationwide trends of the overall STS incidence were inconsistent across countries. A SEER study from the US during 1978 to 2001 revealed that the ASRs significantly increased by 1.2% and 0.8% for Caucasian males and females but declined

| City/County (n = 22) | n   | %   | Crude Rate | ASR  | 95% CI | SRR  | 95% CI |
|----------------------|-----|-----|------------|------|--------|------|--------|
| Northern Region      |     |     |            |      |        |      |        |
| Taipei City          | 526 | 13.14 | 2.23 | 1.79 | 1.63–1.95 | 1.07 | 0.97–1.18 |
| New Taipei City      | 679 | 16.97 | 1.98 | 1.85 | 1.70–1.99 | 1.11 | 1.02–1.21 |
| Taoyuan City         | 279 | 6.97  | 1.61 | 1.54 | 1.36–1.73 | 0.91 | 0.81–1.02 |
| Keelung City         | 83  | 2.07  | 2.37 | 2.19 | 1.69–2.69 | 1.30 | 1.00–1.69 |
| Hsinchu City         | 64  | 1.60  | 1.77 | 1.67 | 1.25–2.08 | 0.99 | 0.77–1.27 |
| Hsinchu County       | 81  | 2.02  | 1.83 | 1.68 | 1.31–2.05 | 0.99 | 0.79–1.24 |
| Yilan County         | 97  | 2.42  | 2.34 | 1.87 | 1.49–2.25 | 1.11 | 0.89–1.38 |
| Miaoli County        | 110 | 2.75  | 2.18 | 1.77 | 1.43–2.11 | 1.05 | 0.86–1.28 |
| Central Region       |     |     |            |      |        |      |        |
| Taichung City        | 407 | 10.17 | 1.74 | 1.65 | 1.48–1.81 | 0.97 | 0.88–1.08 |
| Changhua County      | 228 | 5.70  | 1.93 | 1.69 | 1.46–1.91 | 1.00 | 0.87–1.14 |
| Nantou County        | 87  | 2.17  | 1.81 | 1.47 | 1.14–1.80 | 0.87 | 0.70–1.07 |
| Yunlin County        | 123 | 3.07  | 1.88 | 1.49 | 1.21–1.77 | 0.88 | 0.74–1.05 |
| Southern Region      |     |     |            |      |        |      |        |
| Chiayi City          | 52  | 1.30  | 2.12 | 1.83 | 1.33–2.33 | 1.08 | 0.81–1.44 |
| Chiayi County        | 97  | 2.42  | 1.96 | 1.56 | 1.23–1.89 | 0.92 | 0.75–1.13 |
| Tainan City          | 335 | 8.37  | 1.99 | 1.67 | 1.48–1.85 | 0.99 | 0.88–1.11 |
| Kaohsiung City       | 472 | 11.79 | 1.90 | 1.65 | 1.50–1.80 | 0.97 | 0.88–1.07 |
| Pingtung County      | 155 | 3.87  | 1.94 | 1.60 | 1.34–1.85 | 0.94 | 0.80–1.10 |
| Eastern Region       |     |     |            |      |        |      |        |
| Hualien County       | 62  | 1.55  | 2.00 | 1.62 | 1.20–2.04 | 0.96 | 0.74–1.24 |
| Taitung County       | 43  | 1.07  | 2.03 | 1.56 | 1.08–2.03 | 0.92 | 0.69–1.24 |
| Offshore Islands     |     |     |            |      |        |      |        |
| Penghu County        | 13  | 0.32  | 1.54 | 1.02 | 0.44–1.60 | 0.60 | 0.39–0.94 |
| Kinmen County        | 7   | 0.17  |  ||  ||  ||  |
| Lienchiang County    | 2   | 0.05  |  ||  ||  ||  |
| Total                | 4002| 100  | 1.94 | 1.69 | 1.64–1.74 |  |  |  |
slightly in the black population. However, an Austrian population-based study for the period from 1984 to 2004 failed to demonstrate similar variations in the incidences of STS. In this study, the incidence rates increased significantly from 2003 to 2011 in Taiwan, with an APC of 2.2%. Specifically, the trend was only found in males. In addition, sex-specific variations in APC were also found in different histologic subtypes of STS. In Taiwan, a significant downward trend in APC was only found in females with UPS, whereas the annual changes in the incidence of liposarcoma and other specified sarcoma significantly increased in males. Further investigations are required to elucidate the mechanisms underlying the racial and sex-specific differences and the association with histologic subtypes of STS.

Analysis of the geographic differences revealed a significantly higher incidence of STS in New Taipei City, the city with the highest population compared with the rest area of Taiwan. The relationships between the risk factors, such as pollution and life styles, and the increased incidence of STS also deserve further investigation. Despite that Penghu county had significantly lower rate in this study, the small population size and limited number of registered STS might influence the statistical significance of analysis.

There were several limitations in this study. First, the data acquired from the TCR were restricted to the STS of extremities and trunk wall. Second, due to the restriction of data application from TCR, further classifying of rhabdomyosarcoma and liposarcoma into different subtypes, which clearly have distinct clinical behaviors and cancer biology and might display variable incidence patterns, was not done in the current analysis. Third, the data of NF1-associated malignant nerve sheath tumor was not available. Finally, the different coding systems associated with changes in the allocation of registered data might contribute to effects on the results of incidence trends.

In addition, the acquired data stratified as “other malignancy” may not exclude the nonsarcoma subjects. However, the effect on the conclusion of this study was limited, because they only comprised less than 2.5% of the total number of STS.

CONCLUSIONS

To our best knowledge, this is the first report analyzing the population-based incidence of STS in Taiwan. Based on the data acquired from the nationwide TCR database, the incidence and temporal trends in Taiwanese population of all ages were elucidated. Age, sex, and histologic subtype-specific variations in the incidence rates of STS suggested complexity and diversity of this disease. The novel findings from this analysis include the upward trend of overall STS incidence in male, angiosarcoma has the most prominent male predilection, and a significant geographic variation with the higher incidence in New Taipei City. All of the mentioned above provide important information for additional research plans to elucidate the underlying risk factors associated with STS in Taiwan.

ACKNOWLEDGMENT

We thank the great help of Dr. Shu-Chiung Chiang (Institute of Hospital and Health Care Administration, National Yang-Ming University, email: scchiang0g@gmail.com) for statistics consulting.

REFERENCES

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

2. Fletcher, C.D.M., World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France: IARC Press; 2013.

3. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl. 1994;259:1–31.

4. Levi F, La Vecchia C, Randimbison L, et al. Descriptive epidemiology of soft tissue sarcomas in Vaud, Switzerland. Eur J Cancer. 1999;35:1711–1716.

5. Ross JA, Severson RK, Davis S, et al. Trends in the incidence of soft tissue sarcomas in the United States from 1973 through 1987. Cancer. 1993;72:486–490.

6. Schuurman B, Meyer S, Cuesta MA, et al. Increasing frequency of soft tissue sarcomas in The Netherlands. Ned Tijdschr Geneeskd. 1992;136:1556–1560.

7. Storm HH. Cancers of the soft tissues. Cancer Surv. 1994;19:20–197–217.

8. Kuro SR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveilliance, epidemiology and end results program, 1973–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119:2922–2930.

9. Wibmer C, Leithner A, Zielonke N, et al. Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. Ann Oncol. 2010;21:1106–1111.

10. Ngan R, Wang E, Porter D, et al. Soft-tissue sarcomas in the Asia-Pacific region: a systematic review. Asian Pac J Cancer Prev. 2013;14:6821–6832.

11. Eyre R, Feltbower RG, Muhwandirikwa E, et al. Epidemiology of bone tumours in children and young adults. Pediatr Blood Cancer. 2009;53:941–952.

12. Kang S, Kim HS, Choi ES, et al. Incidence and treatment pattern of extremity soft tissue sarcoma in Korea, 2009–2011: a nationwide study based on the health insurance review and assessment service database. Cancer Res Treat. 2015. doi:10.4143/ct.2014.047. [Epub ahead of print].

13. Hung GY, Hong J, Yen HI, et al. Incidence patterns of primary bone cancer in Taiwan (2003–2010): a population-based study. Ann Surg Oncol. 2014;21:2490–2498.

14. Taiwan Cancer Registry Annual Report. 1995–2011; http://www.hpa.gov.tw/Bhpnet/Web/Stat/StatisticsShow.aspx?No=20091130001. Accessed 25 Feb 2015.

15. Percy C, Fritz A, Ries L. Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, second edition to International Classification of Diseases for Oncology. 3rd ed. Cancer Statistics Branch, Division of Cancer Control and Population Sciences, Surveillance, Epidemiology and End Results Program, National Cancer Institute; 2001. http://seer.cancer.gov/tools/conversion/ICDO2-3manual.pdf. Accessed 18 Sep 2013.

16. Monthly Bulletin of Interior Statistics. 1.1 Number of Villages, Neighborhoods, Households and Resident. 1.4 Indigenous People. 1.6 Resident Population by 5-Year, 10-Year Age Group. 1.11 Resident Population by Single Year of Age. 2013; http://www.moi.gov.tw/stat/month/elist.htm. Accessed 30 Jan 2015.

17. Chiang CJ, Chen YC, Chen CJ, et al., Taiwan Cancer Registry Task F. Cancer trends in Taiwan. Jpn J Clin Oncol. 2010;40:897–904.

18. Chiang CJ, You SL, Chen CJ, et al. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol. 2015;45:291–296.

19. Boyle P, Parkin D. Statistical methods for registries. In: Jensen O, Parkin D, Muir C, eds. Cancer Registration: Principles and Methods. Lyon, France: IARC Scientific Publications, International Agency for Research on Cancer; 1991:126–158.
20. Curado MP, Edwards B, Shin HR, et al. *Cancer Incidence in Five Continents* Vol. IX. Lyon, France: IARC Scientific Publication No. 160. 2007; http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/CI5vol9-A.pdf. Accessed 17 Feb 2015.

21. Joinpoint Regression Program, Version 4.0.4. 2013; http://surveillance.cancer.gov/joinpoint/. Accessed 2 April 2013.

22. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med.* 2000;19:335–351.

23. Rouhani P, Fletcher CD, Devesa SS, et al. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. *Cancer.* 2008;113:616–627.

24. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. *Cancer Res.* 2009;69:7175–7179.

25. Italiano A, Chen CL, Thomas R, et al. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. *Cancer.* 2012;118:5878–5887.

26. Behjati S, Tarpey PS, Sheldon H, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. *Nat Genet.* 2014;46:376–379.

27. Brennan B, Stevens M, Kelsey A, et al. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children’s Cancer and Leukaemia Group between 1991 and 2006. *Pediatr Blood Cancer.* 2010;55:85–90.

28. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. *Cancer Res.* 2002;62:135–140.

29. Murphey MD, Gibson MS, Jennings BT, et al. From the archives of the AFIP: imaging of synovial sarcoma with radiologic-pathologic correlation. *Radiographics.* 2006;26:1543–1565.

30. Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. *Clin Cancer Res.* 2008;14:8191–8197.

31. Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. *Cancer.* 2009;115:2988–2998.

32. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. *Cancer.* 1986;57:2006–2021.

33. Kolberg M, Holand M, Agesen TH, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. *Neuro Oncol.* 2013;15:135–147.